Contact
searchSearch
HMP Global

Biosimilars

Featured Article

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
Addressing and Understanding Challenges Linked With Adopting Biosimilars Into Practice
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
Identifying Pharmacist Knowledge of a Medication Drug Type
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
Most Pharmacists Show Good Grasp of Biosimilar Medications, Study Finds
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
Biosimilar Infliximab Appears Effective in Crohn`s Disease
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
Etanercept Biosimilar is Effective, Well-Tolerated for Rheumatoid Arthritis
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network
News
Biosimilar Infliximab Appears Safe, Effective in IBD Patients
12/15/2017
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the...
12/15/2017
Pharmacy Learning Network
News
Pharmacist Role in Promoting Proper Biosimilar Usage
12/14/2017
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD,...
12/14/2017
Pharmacy Learning Network
News
FDA Approves Another Biosimilar for RA Drug
12/14/2017
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a...
12/14/2017
Pharmacy Learning Network
News
FDA Approves First Biosimilar for Breast, Stomach Cancer
12/01/2017
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a...
12/01/2017
Pharmacy Learning Network
News
The Challenges of Bringing Biosimilars to Market
11/21/2017
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a...
11/21/2017
Pharmacy Learning Network

Newsfeed

News
Communication Needed to Improve Biosimilar Transition, Adherence
10/19/2017
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid...
10/19/2017
Pharmacy Learning Network
News
FDA Approves Amgen`s Cheaper Copy of Arthritis Drug Humira
09/23/2016
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper,...
09/23/2016
Pharmacy Learning Network
News
Novartis Biosimilar Takes Aim at Amgen`s Enbrel
10/23/2015
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis...
10/23/2015
Pharmacy Learning Network
News
FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
08/28/2015
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday...
08/28/2015
Pharmacy Learning Network
News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Cleviprex Recalled Due to Lack of Sterility Assurance
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Nystatin Cream Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
PharmLaw
Florida Laboratory to Pay $9.8 Million to Resolve FCA Allegations Over Physician Compensation
07/22/2026
Grace Taylor, MS, MA
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to...
07/22/2026
Pharmacy Learning Network
News
Clomiphene Citrate Recalled Due to CGMP Deviations
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
Bortezomib Injections Recalled Due to Lack of Sterility Assurance
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network

Insights

Interactive Features

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use